Division of State Programs-Management Reporting Tool (DSP- MRT)

SPF Rx Unique Items DSP-MRT Supplement

#### OMB No: XXXX-XXXX

#### Expiration Date: XX/XX/XXXX

**Contents**

[Administration 1](#_bookmark0)

[Grantee Information 1](#_bookmark1)

[Sub-State Information 1](#_bookmark2)

[Subrecipients 1](#_bookmark3)

[High-Need Communities 1](#_bookmark4)

[Needs Assessment 2](#_bookmark5)

[Needs Assessment 2](#_bookmark6)

[Accomplishments and Barriers/Challenges 2](#_bookmark7)

[Capacity 3](#_bookmark8)

[Membership 3](#_bookmark9)

[Advisory Council and Other Workgroup Meetings 3](#_bookmark10)

[Other Opioid-Specific Workgroup Activities 3](#_bookmark11)

[Grantee Funding Resources 4](#_bookmark12)

[Other Resources 4](#_bookmark13)

[Policies, Regulations, and Laws 4](#_bookmark14)

[Data Infrastructure 5](#_bookmark15)

[Training and Technical Assistance (TA) 6](#_bookmark16)

[Accomplishments and Barriers/Challenges 7](#_bookmark17)

[Planning 8](#_bookmark18)

[Strategic Plan 8](#_bookmark19)

[Accomplishments and Barriers/Challenges 8](#_bookmark20)

[Behavioral Health Disparities 9](#_bookmark21)

[Disparities Impact Statement (DIS) 9](#_bookmark22)

[Population(s) Experiencing the Disparity 9](#_bookmark23)

[Focus and Data Gaps 9](#_bookmark24)

[Access to Prevention Efforts 9](#_bookmark25)

[Use and Reach of Prevention Efforts 9](#_bookmark26)

[Outcomes of Prevention Efforts 9](#_bookmark27)

[Accomplishments and Barriers/Challenges 9](#_bookmark28)

[Implementation 10](#_bookmark29)

[Community-Based Social Marketing/Public Education Plan 10](#_bookmark33)

[Subrecipient Progress 10](#_bookmark31)

[Promising Approaches and Innovations 10](#_bookmark32)

[Use of Federal Toolkits/Guidelines 10](#_bookmark30)

[Accomplishments and Barriers/Challenges 11](#_bookmark34)

[Evaluation 12](#_bookmark35)

[Evaluation Plan 12](#_bookmark36)

[Evaluation Report 12](#_bookmark37)

[Other Document 12](#_bookmark38)

[Accomplishments and Barriers/Challenges 12](#_bookmark39)

[Sustainability 13](#_bookmark40)

[Accomplishments and Barriers/Challenges 13](#_bookmark41)

**Note**: This document is intended as a supplement to the Division of State Programs- Management Reporting Tool (DSP-MRT) for the Strategic Prevention Framework for Prescription Drugs (SPF Rx) grant program. Please refer to the DSP-MRT document where applicable.

# Administration

## Grantee Information

See DSP-MRT.

## Sub-State Information

See DSP-MRT.

## Subrecipients

See DSP-MRT.

## High-Need Communities

See DSP-MRT.

# Needs Assessment

## Needs Assessment

See DSP-MRT.

Please note that a Needs Assessment is not required for SPF Rx.

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Capacity

## Membership

See DSP-MRT.

## Advisory Council and Other Workgroup Meetings

See DSP-MRT.

## Other Opioid-Specific Workgroup Activities

Use this section to enter information about opioid-specific workgroups outside of your State/Tribal Epidemiological Outcomes Workgroup (SEOW/TEOW).

Information about SEOW/TEOW is reported in a separate section. The section includes questions regarding leveraging resources, including state-/grantee-level opioid workgroups and grantee-level funding resources.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| Do you have a state-/grantee-level opioid workgroup? | * Yes
* No
 |
| Does your opioid workgroup serve as your SPF-Rx Advisory Council?(This item will only appear if YES is selected for the first item in this section.) | * Yes
* No
 |
| Does a state/grantee-wide strategic plan exist addressing opioid issues, including prevention of misuse, treatment, and overdose prevention? | * Yes
* No
 |
| Is there an opioid-focused taskforce out of your governor’s office? | * Yes
* No
 |
| How has the opioid-focused taskforce out of your governor’s office informed the SPF-Rx project?(This item will only appear if YES is selected for the previous item in this section.) | Free text |
| Is your SPF-Rx strategic plan integrated into or harmonized with the state/grantee-wide opioid strategic plan?(This item will only appear if YES is selected for the first item in this section.) | * Yes
* No
 |

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| Have you engaged in efforts to coordinate opioid funding streams during this reporting period? | * Yes
* No
 |
| Please describe your efforts to coordinate opioid funding streams during this reporting period?(This item will only appear if YES is selected for the previous item in this section.) | Free text |

## Grantee Funding Resources

See DSP-MRT.

## Other Resources

### Policies, Regulations, and Laws

Use this section to enter information regarding the existence of policies, regulations, and laws related to prescribing or dispensing opioids in your state, tribal area, or jurisdiction. Once you complete this section, you will only update it if there are any revisions or additional changes related to your policies, regulations, or laws.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| ***Indicate if guidelines/regulations currently exist in your state/jurisdiction related to any of the following:***Required universal prescriber registration with the PDMP | * Yes
* No
 |
| Doctors can assign authorized delegates to access the PDMP | * Yes
* No
 |
| Requirements for prescribers to query PDMP before prescribing opioids in certain conditions (e.g., for more than short-term use) | * Yes
* No
 |
| Pharmacists have a set time frame for uploading opioid dispensing data | * Yes
* No
 |
| If yes, what is the time frame for uploading opioid dispensing data?(This item will only appear if YES is selected in previous item.) | Free text |
| PDMP patient records and electronic health records are linked in at least one large health care system | * Yes
* No
 |

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| PDMP records are linked with vital records (e.g., deaths) | * Yes
* No
 |
| PDMP data can be used for public health surveillance, prevention, and research | * Yes
* No
 |
| PDMP produces regular reports that summarize key state or regional statistics of interest | * Yes
* No
 |
| PDMP produces unsolicited reports | * Yes
* No
 |
| If yes, reports are for which groups?(This item will only appear if YES is selected in previous item.) | * Prescribers
* Dispensers
* Licensing boards
* Law enforcement agencies
* Other group(s) (Specify)
 |
| Interstate agreements to share PDMP data | * Yes
* No
 |
| Requirements for prescribers to receive training on safe opioid prescribing | * Yes
* No
 |
| Limit to dose of opioid prescription (e.g., 90 MME/day) without special approval | * Yes
* No
 |
| Limit to the duration of opioid prescription for noncancer patients without special approval | * Yes
* No
 |
| Requirements that pain clinics must be regularly certified by the state medical board | * Yes
* No
* N/A (State does not have pain clinics)
 |
| Requirements that pain clinics must be owned and operated by a licensed physician | * Yes
* No
* N/A (State does not have pain clinics)
 |
| Other relevant PDMP guidelines or regulations not captured above? | Free text |

### Data Infrastructure

Use this section to enter information regarding data infrastructure and related activities.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| ***During this reporting period, have you engaged in efforts to:*** |
| … Enhance access to PDMP data at the grantee/state level? | * Yes
* No
 |
| … Enhance access to PDMP data at the subrecipient level? | * Yes
* No
 |
| … Enhance usage of PDMP data at the grantee/state level? | * Yes
* No
 |
| … Enhance usage of PDMP data at the subrecipient level? | * Yes
* No
 |
| … Enhance the quality of PDMP data collected? | * Yes
* No
 |
| … Increase registration for the PDMP? | * Yes
* No
 |
| … Increase voluntary PDMP enrollment? | * Yes
* No
 |
| … Increase mandatory PDMP enrollment? | * Yes
* No
 |
| … Increase timely data upload by pharmacists to the PDMP? | * Yes
* No
 |
| … Integrate PDMPs with electronic health records? | * Yes
* No
 |
| … Integrate PDMPs with health information exchanges? | * Yes
* No
 |
| … Increase reports to prescribers? | * Yes
* No
 |
| … Increase reports to dispensers? | * Yes
* No
 |
| … Increase reports to licensing boards? | * Yes
* No
 |
| Please describe any other efforts to improve data infrastructure that havenot been captured. | Free text |

## Training and Technical Assistance (TA)

See DSP-MRT.

*Please note that this section does not include prescriber education trainings, which are reported in the Implementation section of this progress report and the Annual Implementation Instrument.*

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Planning

## Strategic Plan

Ensure that your strategic plan clearly explains how PDMP and/or other epidemiological data were used to identify communities with high rates of prescription drug misuse, focuses on improving PDMP partnerships and access/use of PDMP data, identifies data gaps, and addresses program sustainability.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| Upload document | Browse |
| Provide a brief description of your document and, if relevant, any changes made to your document between the previous version and this one. | Free text |
| Were PDMP data incorporated into your strategic plan? | * Yes
* No
 |

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Behavioral Health Disparities

## Disparities Impact Statement (DIS)

See DSP-MRT.

## Population(s) Experiencing the Disparity

See DSP-MRT.

## Focus and Data Gaps

See DSP-MRT.

## Access to Prevention Efforts

See DSP-MRT.

## Use and Reach of Prevention Efforts

See DSP-MRT.

## Outcomes of Prevention Efforts

See DSP-MRT.

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Implementation

**Use of Federal Toolkits/Guidelines**

Federal resources have been developed that can assist grantees in training and increasing capacity around the prevention of opioid misuse and overdose. Please describe how the tools noted below were used.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| Did the grantee/state use SAMHSA’s Opioid Overdose Prevention Toolkit? | * Yes
* No
 |
| How was SAMHSA’s Opioid Overdose Prevention Toolkit used? (This item will only appear if YES is selected for the prior item. | Free text |
| Did the grantee/state use the CDC’s Guidelines for Prescribing Opioids for Chronic Pain? | * Yes
* No
 |
| How were the CDC’s Guidelines for Prescribing Opioids for Chronic Pain used?(This item will only appear if YES is selected for the prior item. | Free text |

**Subrecipient Progress**

See DSP-MRT.

**Promising Approaches and Innovations**

See DSP-MRT

## Community-Based Social Marketing/Public Education Plan

Upload and provide a brief description of your community-based social marketing/public education plan.

|  |  |
| --- | --- |
| **Item** | **Response Options** |
| Upload document | Browse |
| Provide a brief description of your document and, if relevant, any changes made to your document between the previous version and this one. | Free text |

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Evaluation

## Evaluation Plan

See DSP-MRT.

## Evaluation Report

See DSP-MRT.

## Other Document

See DSP-MRT.

## Accomplishments and Barriers/Challenges

See DSP-MRT.

# Sustainability

## Accomplishments and Barriers/Challenges

See DSP-MRT.